Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ORIN-1001 by Shanghai Fosun Pharmaceutical (Group) for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
ORIN-1001 is under clinical development by Shanghai Fosun Pharmaceutical (Group) and currently in Phase II for Human Epidermal Growth Factor...
ORIN-1001 by Shanghai Fosun Pharmaceutical (Group) for Solid Tumor: Likelihood of Approval
ORIN-1001 is under clinical development by Shanghai Fosun Pharmaceutical (Group) and currently in Phase II for Solid Tumor. According to...
ORIN-1001 by Shanghai Fosun Pharmaceutical (Group) for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
ORIN-1001 is under clinical development by Shanghai Fosun Pharmaceutical (Group) and currently in Phase II for Triple-Negative Breast Cancer (TNBC)....
ORIN-1001 by Shanghai Fosun Pharmaceutical (Group) for Metastatic Breast Cancer: Likelihood of Approval
ORIN-1001 is under clinical development by Shanghai Fosun Pharmaceutical (Group) and currently in Phase II for Metastatic Breast Cancer. According...